

The Top 3 Biotech Stocks All Investors Should Own

There's plenty of growth in store for biotech and pharmaceuticals.

Over the next seven years, according to Grand View Research, the global biotech industry could be worth up to \$2.5 trillion, growing at a CAGR of about 16%.

There's also incredible new innovation in genetics and technology, creating new life-saving and life enhancing opportunities. Big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls created by patent expirations.

With a good deal of catalysts, here are the top three biotech stocks to consider.

Top Stock – TG Therapeutics (TGTX)

Shares of TGTX have been explosive.

After running from about \$22 to \$32, the stock could see further upside.

“The company just announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for ublituximab, the Company's investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ, the Company's once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL),” as noted in a recent press release.

Top Stock – Anavex Life Sciences (AVXL)

While the stock recently pulled back, use the weakness as opportunity. Near-term, we'd like to see AVXL break from consolidation and potentially test prior highs near \$30.

All as it progresses with a potential treatment for Alzheimer's disease.

All after the company reported that the “predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary and secondary clinical efficacy endpoints from the proof-of-concept randomized, double-blind, placebo-controlled Phase 2 trial that randomized 132 patients with Parkinson's disease dementia equally to target doses of 30mg, 50mg ANAVEX[®]2-73 or placebo, respectively,” as noted in a company press release.

With further progress, we could be looking at a massive game-changer here for Alzheimer's.

Top Stock – CRISPR Therapeutics (CRSP)

Cathie Wood's ARK Invest just bought another 248,000 shares of the stock. That's after ARK bought 404,000 shares late last week. In addition, CRSP has become wildly oversold at triple bottom support dating back to November 2020, with oversold extensions on RSI, MACD, and Williams' %R. Even better, reportedly, the company will report data from a Phase 1 study of CTX110 for relapsed or refractory B-cell malignancies later this year.